Advances in tumor treatment with labeled somatostatin analogues

The values of 90Y-octreotide and 177Lu -octreotate in tumor treatment were briefly reviewed. The rationale of clinical applications, the distribution of radiopeptide in tumor and normal tissues and application of renal protective agents were revewed as well. Tumor with potential therapeutic responses are many such as non-iodide avid cancer of thyroid gland, Hurthle cell thyroid cancer, medullary thyroid cancer, neuroendo-gastro-entero-pancreatic (GEP) tumor, small cell 1 cancer, carcinoid tumors and pheochromocytoma. The current state of clinical use of radiopeeptide for therapy of tumors, the development of new compounds and future development, the dosage of radiopeptide for tumor treatment with well tolerated and remarkable clinical benefit were presented. (authors)